GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Long-Term Debt

BriaCell Therapeutics (TSX:BCT) Long-Term Debt : C$0.00 Mil (As of Jul. 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Long-Term Debt?

BriaCell Therapeutics's Long-Term Debt for the quarter that ended in Jul. 2024 was C$0.00 Mil.

BriaCell Therapeutics Long-Term Debt Historical Data

The historical data trend for BriaCell Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Long-Term Debt Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.03 - - -

BriaCell Therapeutics Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics  (TSX:BCT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BriaCell Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Long-Term Debt
Comparable Companies
TSX:ONC TSX:TH XCNQ:DTC TSX:EPRX TSXV:ARCH TSXV:NGEN TSXV:MIR XCNQ:ACOG NEOE:MMED TSX:MBX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
BCTX:USA 8BT:Germany
Address
235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
Website
https://www.briacell.com
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Jamieson Bondarenko Director
Marc Lustig 10% Security Holder, Director
Gadi Levin Senior Officer
William Williams Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines